Tüzün E - Search Results

1

Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis.

Tüzün E, Scott BG, Goluszko E, Higgs S, Christadoss P. Tüzün E, et al. J Immunol. 2003 Oct 1;171(7):3847-54. doi: 10.4049/jimmunol.171.7.3847. J Immunol. 2003. PMID: 14500686

2

Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production.

Deng C, Goluszko E, Tüzün E, Yang H, Christadoss P. Deng C, et al. Among authors: tuzun e. J Immunol. 2002 Jul 15;169(2):1077-83. doi: 10.4049/jimmunol.169.2.1077. J Immunol. 2002. PMID: 12097416

3

B7-1 costimulatory molecule is critical for the development of experimental autoimmune myasthenia gravis.

Poussin MA, Tüzün E, Goluszko E, Scott BG, Yang H, Franco JU, Christadoss P. Poussin MA, et al. Among authors: tuzun e. J Immunol. 2003 Apr 15;170(8):4389-96. doi: 10.4049/jimmunol.170.8.4389. J Immunol. 2003. PMID: 12682276

4

Circulating immune complexes augment severity of antibody-mediated myasthenia gravis in hypogammaglobulinemic RIIIS/J mice.

Tüzün E, Scott BG, Yang H, Wu B, Goluszko E, Guigneaux M, Higgs S, Christadoss P. Tüzün E, et al. J Immunol. 2004 May 1;172(9):5743-52. doi: 10.4049/jimmunol.172.9.5743. J Immunol. 2004. PMID: 15100321

5

ICOS is essential for the development of experimental autoimmune myasthenia gravis.

Scott BG, Yang H, Tüzün E, Dong C, Flavell RA, Christadoss P. Scott BG, et al. Among authors: tuzun e. J Neuroimmunol. 2004 Aug;153(1-2):16-25. doi: 10.1016/j.jneuroim.2004.04.019. J Neuroimmunol. 2004. PMID: 15265659

6

Etanercept treatment in corticosteroid-dependent myasthenia gravis.

Rowin J, Meriggioli MN, Tüzün E, Leurgans S, Christadoss P. Rowin J, et al. Among authors: tuzun e. Neurology. 2004 Dec 28;63(12):2390-2. doi: 10.1212/01.wnl.0000147242.92691.71. Neurology. 2004. PMID: 15623708 Clinical Trial.

7

Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment.

Tüzün E, Meriggioli MN, Rowin J, Yang H, Christadoss P. Tüzün E, et al. J Autoimmun. 2005 May;24(3):261-8. doi: 10.1016/j.jaut.2005.01.013. J Autoimmun. 2005. PMID: 15848049 Clinical Trial.

8

IL-1 receptor antagonist-mediated therapeutic effect in murine myasthenia gravis is associated with suppressed serum proinflammatory cytokines, C3, and anti-acetylcholine receptor IgG1.

Yang H, Tüzün E, Alagappan D, Yu X, Scott BG, Ischenko A, Christadoss P. Yang H, et al. Among authors: tuzun e. J Immunol. 2005 Aug 1;175(3):2018-25. doi: 10.4049/jimmunol.175.3.2018. J Immunol. 2005. PMID: 16034147

9

The cDNA of mouse skeletal muscle transcribe for both isoforms 1 and 2 of acetylcholine receptor alpha subunit.

Saini SS, Tüzün E, Christadoss P. Saini SS, et al. Among authors: tuzun e. J Neuroimmunol. 2005 Dec;169(1-2):177-9. doi: 10.1016/j.jneuroim.2005.08.013. Epub 2005 Sep 26. J Neuroimmunol. 2005. PMID: 16185772

10

Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis.

Tüzün E, Saini SS, Ghosh S, Rowin J, Meriggioli MN, Christadoss P. Tüzün E, et al. Neuromuscul Disord. 2006 Feb;16(2):137-43. doi: 10.1016/j.nmd.2005.11.005. Epub 2006 Jan 19. Neuromuscul Disord. 2006. PMID: 16427283

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

382 results

Search Page

Filters